Please Wait
Applying Filters...
menu
    • menu
    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    ATH434

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alterity Therapeutics Showcases Ath434's Positive Effect On MSA
    Alterity Therapeutics Showcases Ath434's Positive Effect On MSA

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184418/0/en/Alterity-Therapeutics-Presents-Promising-Impact-of-ATH434-on-Orthostatic-Hypotension-and-Disease-Progression-in-MSA-at-the-36th-International-Symposium-on-the-Autonomic-Nervous-Sys.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report
    Alterity Therapeutics Releases Q1 FY26 Cash Flow Report

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178235/0/en/Alterity-Therapeutics-Appendix-4C-Q1-FY26-Quarterly-Cash-Flow-Report.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress
    Alterity Reveals Positive ATH434 Ph 2 Trial Results At Congress

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Alterity Therapeutics To Present At 2025 Parkinson's Disease
    Alterity Therapeutics To Present At 2025 Parkinson's Disease

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160282/0/en/Alterity-Therapeutics-to-Deliver-Multiple-Presentations-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial

    10 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/10/3059151/0/en/Alterity-Therapeutics-Presents-Encouraging-New-Data-from-its-ATH434-Phase-2-Trial-in-Multiple-System-Atrophy-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Apr 2025
    Share Share
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results

    03 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/03/3055030/0/en/Alterity-Therapeutics-to-Deliver-an-Oral-Presentation-of-the-Positive-ATH434-Phase-2-Trial-Results-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.